NEW YORK (GenomeWeb News) – Med BioGene had no revenues and a loss of $366,345, or breakeven on a per-share basis, for full-year 2012, the company disclosed in a document filed with Canadian regulators today.

The revenue figure compares to $2.1 million a year ago. The Vancouver, British Columbia-based firm recorded a profit of $1.6 million, or $.02 per share, for FY 2011.

The drop in revenues results from the amendment of a licensing deal with its commercial partner Precision Therapeutics.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.